We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

090430:KRXAmorepacific Corporation Analysis

Data as of 2026-06-09 - not real-time

₩112,000.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Amorepacific is trading well below its 20‑day, 50‑day and 200‑day simple moving averages, suggesting a price lag despite solid fundamentals. RSI hovering around the low‑40s hints at a mildly oversold condition, while the bearish MACD histogram confirms recent downward momentum. The stock remains comfortably above its identified support level, and volume trends are increasing, providing a cushion against further short‑term declines. Valuation metrics are compelling: the discounted cash‑flow model places fair value near the mid‑120 k range, implying more than 50% upside from the current price, and the forward P/E is modest at under 17. Dividend sustainability looks sound with a 1.2% yield supported by a payout ratio below 40% and ample cash generation. However, the company carries a high debt‑to‑equity ratio, though its cash reserves comfortably exceed total debt, mitigating balance‑sheet concerns. Analyst sentiment is strongly positive, with a consensus “strong buy” and target prices near 180 k, while market sentiment is in an “Extreme Greed” phase.
The sector’s defensive nature and the brand’s diversified portfolio provide stability, but the 30‑day volatility exceeds 55% and the beta is low, indicating limited market‑wide price swings but heightened idiosyncratic risk. Given these dynamics, the stock presents a clear value opportunity with upside potential, tempered by short‑term technical weakness and balance‑sheet leverage that warrants cautious positioning.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below multiple moving averages indicating technical weakness
  • Support level holding with rising volume
  • High short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Substantial upside to DCF fair value
  • Strong cash generation and sustainable dividend
  • Analyst consensus strong‑buy and elevated target prices

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Diversified premium brand portfolio with global reach
  • Robust balance sheet with cash exceeding debt
  • Consistent revenue growth and high gross margins

Key Metrics & Analysis

Financial Health

Revenue Growth6.40%
Profit Margin5.40%
P/E Ratio17.0
ROE4.43%
ROA3.10%
Debt/Equity6.44
Op. Cash Flow₩526.3B
Free Cash Flow₩442.7B

Technical Analysis

TrendNeutral
RSI40.9
Support₩102,100.00
Resistance₩132,700.00
MA 20₩116,980.00
MA 50₩127,564.00
MA 200₩127,531.00
MACDBearish
VolumeIncreasing
Fear & Greed Index89.7

Valuation

Fair Value₩121,286.26
Target Price₩173,370.38
Upside/Downside54.79%
GradeUndervalued
TypeBlend
Dividend Yield1.18%

Risk Assessment

Beta0.11
Volatility55.96%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.